BioXcel Therapeutics
BTAI
103 hedge funds and large institutions have $388M invested in BioXcel Therapeutics in 2021 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 50 increasing their positions, 25 reducing their positions, and 17 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 25
3% more capital invested
Capital invested by funds: $378M → $388M (+$9.86M)
0.07% less ownership
Funds ownership: 2.93% → 2.86% (-0.07%)
4% less call options, than puts
Call options by funds: $6.54M | Put options by funds: $6.84M
5% less funds holding
Funds holding: 108 → 103 (-5)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.4M |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
+$5.14M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$3.57M |
| 4 |
BlackRock
New York
|
+$2.32M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$6.86M |
| 2 |
CCM
CAAS Capital Management
New York
|
-$6.75M |
| 3 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$5.63M |
| 4 |
LM
Luminus Management
Houston,
Texas
|
-$4.57M |
| 5 |
Blackstone Inc
New York
|
-$4.36M |
BTAI Hedge Fund Activity: Q3 2021 in Review
103 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q3 2021, worth a combined $388M — up 2.6% from $378M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of BTAI and 12 opened new positions — a net loss of 5 holders — while 25 trimmed existing stakes and 50 added.
The largest buyer was Fidelity Investments, adding an estimated $18.4M. The largest seller was Altshuler Shaham, cutting an estimated $6.86M.
- 103 institutional investors held BioXcel Therapeutics (BTAI) as of Q3 2021, down from 108 in Q2 2021.
- Funds reported $388M of BioXcel Therapeutics stock for Q3 2021, up 2.6% quarter-over-quarter.
- 12 funds opened new BioXcel Therapeutics positions in Q3 2021 and 17 closed out, a net change of -5 holders.
- The largest BioXcel Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $18.4M added.
- The largest BioXcel Therapeutics seller in Q3 2021 was Altshuler Shaham, an estimated $6.86M sold.
Based on aggregated 13F filings for Q3 2021.